Triana Biomedicines closed a $120 million Series B financing led by Pfizer Ventures and other investors to advance its molecular glue degrader pipeline into clinical development. The oversubscribed round aims to fund proof‑of‑concept studies and IND‑enabling work for the lead program. Triana’s platform discovers small molecules that reprogram E3 ligases to ubiquitinate disease proteins, a strategy known as molecular glues that can target previously undruggable proteins. The company said funds will accelerate preclinical development and the transition to first‑in‑human trials. Investors cited the modality’s recent validation and potential for rapid clinical translation. Triana intends to use the new capital to broaden its pipeline and prepare regulatory filings for its lead degrader candidate.